[
  {
    "ts": null,
    "headline": "Viatris Inc. stock rises Thursday, outperforms market",
    "summary": "Viatris Inc. stock rises Thursday, outperforms market",
    "url": "https://finnhub.io/api/news?id=980a2708adfee4e89e9fd3006ca9d3d9ab24158d080c817c3b99e15d557e87e7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750958280,
      "headline": "Viatris Inc. stock rises Thursday, outperforms market",
      "id": 135612975,
      "image": "",
      "related": "VTRS",
      "source": "MarketWatch",
      "summary": "Viatris Inc. stock rises Thursday, outperforms market",
      "url": "https://finnhub.io/api/news?id=980a2708adfee4e89e9fd3006ca9d3d9ab24158d080c817c3b99e15d557e87e7"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia",
    "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) in treating presbyopia. Presbyopia is the progressive loss of the ability to focus on close objects that results in blurred near vision and eye strain, particularly in dim lighting conditions.",
    "url": "https://finnhub.io/api/news?id=119a5714c773e00f63d3a04a629f7ffb878269ac18e3c36055535301a9230846",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750935300,
      "headline": "Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia",
      "id": 135554747,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) in treating presbyopia. Presbyopia is the progressive loss of the ability to focus on close objects that results in blurred near vision and eye strain, particularly in dim lighting conditions.",
      "url": "https://finnhub.io/api/news?id=119a5714c773e00f63d3a04a629f7ffb878269ac18e3c36055535301a9230846"
    }
  },
  {
    "ts": null,
    "headline": "Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA",
    "summary": "Theravance Biopharma, Inc. (\"Theravance Biopharma\" or the \"Company\") (NASDAQ: TBPH) today announced that Viatris Inc. (\"Viatris\"), has secured regulatory approval from China's National Medical Products Administration (NMPA) for YUPELRI® (revefenacin) inhalation solution, the first once–daily nebulized long–acting muscarinic antagonist (LAMA) approved for maintenance treatment of chronic obstructive pulmonary disease (COPD) in China.",
    "url": "https://finnhub.io/api/news?id=80b9d5e226abb8e1be3e3410234e1583d424a19d710565feaf1252a1b06d68a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750932000,
      "headline": "Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA",
      "id": 135554748,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Theravance Biopharma, Inc. (\"Theravance Biopharma\" or the \"Company\") (NASDAQ: TBPH) today announced that Viatris Inc. (\"Viatris\"), has secured regulatory approval from China's National Medical Products Administration (NMPA) for YUPELRI® (revefenacin) inhalation solution, the first once–daily nebulized long–acting muscarinic antagonist (LAMA) approved for maintenance treatment of chronic obstructive pulmonary disease (COPD) in China.",
      "url": "https://finnhub.io/api/news?id=80b9d5e226abb8e1be3e3410234e1583d424a19d710565feaf1252a1b06d68a5"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Inc. Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia",
    "summary": "Viatris Inc. announced positive top-line results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 in treating presbyopia. Presbyopia is the progressive loss of the ability to focus on...",
    "url": "https://finnhub.io/api/news?id=70babe05de8001fec88af586bfb8d0a310bae9ff857f399aeb9e8981ea1e7e69",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750924223,
      "headline": "Viatris Inc. Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia",
      "id": 135555195,
      "image": "",
      "related": "VTRS",
      "source": "Finnhub",
      "summary": "Viatris Inc. announced positive top-line results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 in treating presbyopia. Presbyopia is the progressive loss of the ability to focus on...",
      "url": "https://finnhub.io/api/news?id=70babe05de8001fec88af586bfb8d0a310bae9ff857f399aeb9e8981ea1e7e69"
    }
  }
]